URGN vs AVLN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
URGN · UroGen Pharma Ltd$24.75 ▼ 3.81%
AVLN · Avalyn Pharma$29.15 ▲ 9.30%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- URGN +3.9%
- AVLN -1.2%
Head to head
| Metric | URGN | AVLN |
|---|---|---|
| Price | $24.75 | $29.15 |
| Change today | ▼ 3.81% | ▲ 9.30% |
| Market cap | $1.21B | $1.29B |
| Return, 3 months | -46.6% | -15.7% |
| Return, year to date | +5.7% | – |
| Return, 1 year | +6.5% | – |
| P/E (TTM) | – | – |
| P/B | -9.7 | 3.2 |
| P/E percentile vs own 5y | 5th | 89th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +199.2% | – |
| Net profit growth (YoY) | +71.3% | -43.3% |
| Gross margin | 90.8% | – |
| Operating margin | -35.3% | – |
| Net margin | -51.7% | – |
| Return on equity | – | -25.9% |
| Analyst target vs. price | +143.2% | +93.2% |
| Analyst buy share | 80% | 100% |
| RSI (14) | 18 | 60 |
| 30-day volatility | 72.8% | 63.5% |
| Max drawdown, 1 year | -50.8% | -40.6% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AVLN is the largest of the group by market value.
- AVLN has been the calmest stock over the last 30 days.